Global Aortic Stent Grafts Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Aortic Stent Grafts Market Analysis

The aortic stent grafts market is experiencing significant growth, driven by advancements in medical technology and an increasing prevalence of cardiovascular diseases, particularly among the aging population. Aortic stent grafts are primarily used for Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aneurysm Repair (TEVAR), offering a minimally invasive solution for aortic aneurysms and other vascular diseases. The market is witnessing innovations such as lower-profile stent grafts, balloon-expandable devices, and custom-made stent grafts designed to offer better flexibility, improved patient outcomes, and reduced procedural complications. Advancements in biocompatible materials, advanced imaging techniques, and stent graft configurations are enhancing the performance of these devices, enabling more precise treatments. Companies such as Medtronic, W.L. Gore & Associates, Terumo Aortic, and Cook Medical are at the forefront, focusing on improving the design, compatibility, and ease of use of these devices. The rising global burden of cardiovascular diseases, combined with increasing awareness and improved healthcare infrastructure, is expected to drive the growth of the aortic stent graft market during the forecast period. Key regions, including North America, Europe, and Asia-Pacific, are anticipated to lead in terms of market share.

Aortic Stent Grafts Market Size

The global aortic stent grafts market size was valued at USD 3.77 billion in 2024 and is projected to reach USD 5.76 billion by 2032, with a CAGR of 5.41% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Aortic Stent Grafts Market Trends

“Rising Shift towards Minimally Invasive Procedures”

The global aortic stent grafts market is experiencing robust growth, driven by the increasing incidence of aortic aneurysms, cardiovascular diseases, and the rising geriatric population. A key trend shaping the market is the shift towards minimally invasive surgeries, as these devices offer a less traumatic alternative to traditional surgery. Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aneurysm Repair (TEVAR) have become increasingly preferred due to their ability to reduce recovery times and lower the risk of complications. Companies such as Medtronic and W.L. Gore & Associates are innovating with advanced stent graft designs, such as the GORE EXCLUDER AAA Endoprosthesis, which provides better durability and flexibility for treating abdominal aortic aneurysms. Additionally, advancements in biocompatible materials and customized grafts are enhancing device performance, contributing to the increasing adoption of aortic stent grafts in clinical settings. With growing healthcare investments in regions such as Asia-Pacific and North America, the market is expected to expand steadily.

Report Scope and Aortic Stent Grafts Market Segmentation  

Aortic Stent Grafts Market Definition

Aortic stent grafts are medical devices used to treat aortic aneurysms and other vascular diseases by reinforcing the weakened areas of the aorta. They consist of a stent (a mesh-like structure) and a graft (a fabric or polymer material), which is placed within the aorta using a minimally invasive procedure known as Endovascular Aneurysm Repair (EVAR) or Thoracic Endovascular Aneurysm Repair (TEVAR). The stent graft is deployed to reinforce and seal the aorta, preventing the aneurysm from rupturing and improving blood flow.

Aortic Stent Grafts Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases is a significant market driver for aortic stent grafts. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for nearly 17.90 million deaths each year, which represents 31% of all global deaths. This increase in cardiovascular conditions, including aortic aneurysms and hypertension, has created a growing demand for endovascular treatments such as aortic stent grafts. As a result, the demand for minimally invasive treatments such as Endovascular Aneurysm Repair (EVAR) is rising. This shift towards less invasive procedures improves patient outcomes and drives the aortic stent grafts market as a critical solution for managing complex cardiovascular conditions, especially in aging populations.

• Growing Geriatric Population

The growing geriatric population is a crucial market driver for aortic stent grafts, as older individuals are more susceptible to aortic diseases, including aneurysms. According to the United Nations, the global population aged 60 years and older is expected to rise from 1 billion in 2020 to 2.1 billion by 2050, representing over 20% of the global population. This demographic shift increases the prevalence of age-related cardiovascular conditions, such as aortic aneurysms and aortic dissections, which are more common in older adults. Studies have shown that abdominal aortic aneurysms (AAA) occur in approximately 5-10% of individuals aged 65 and older, significantly raising the demand for treatments such as Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aneurysm Repair (TEVAR). As a result, the increasing number of elderly patients drives the need for aortic stent grafts, propelling market growth as healthcare systems seek advanced, minimally invasive solutions to manage these conditions.

Opportunities

• Growing Technological Advancements in Medical Technology

Advancements in medical technology have significantly improved the effectiveness and safety of aortic stent graft procedures, presenting a major opportunity in the market. Innovations in stent graft materials, such as biocompatible fabrics and flexible metal alloys, enhance the durability and adaptability of the devices, allowing for better integration with the aorta and reducing the risk of complications. Companies such as Medtronic and W.L. Gore & Associates are at the forefront of these advancements. For instance, Medtronic's GORE EXCLUDER AAA Endoprosthesis has revolutionized the treatment of abdominal aortic aneurysms (AAA) with its advanced material and design, offering a more reliable seal and improved patient outcomes. W.L. Gore & Associates introduced the GORE VIABAHN VBX Balloon Expandable Endoprosthesis, which provides greater flexibility and a wider range of applications for complex vascular diseases. These advancements improve patient recovery times and expand the market for aortic stent grafts, positioning companies to capitalize on growing demand for high-performance, minimally invasive treatment options.

• Improved Healthcare Infrastructure

Improved healthcare infrastructure, especially in emerging markets such as Asia-Pacific, presents a significant market opportunity for aortic stent grafts. As countries in this region, including China, India, and South Korea, continue to invest in healthcare systems, the adoption of advanced medical technologies, such as aortic stent grafts, has rapidly increased. For instance, China has witnessed a surge in the use of minimally invasive procedures due to its growing healthcare budget and modernization of hospitals. This shift is driven by a rise in cardiovascular diseases, alongside the country's expanding geriatric population. In India, healthcare reforms and increased healthcare expenditure have improved access to advanced treatments, leading to a growing demand for Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aneurysm Repair (TEVAR). With these markets now more equipped to handle complex procedures, companies such as Medtronic and Terumo Aortic are capitalizing on these opportunities, introducing innovative stent graft solutions that cater to the evolving needs of these rapidly developing healthcare systems. As a result, improved infrastructure is significantly fueling the growth of the aortic stent graft market in these regions.

Restraints/Challenges

• High Costs of Treatment

The high cost of treatment associated with aortic stent grafts presents a significant challenge for the market, limiting their accessibility, especially in developing regions or for patients without adequate insurance coverage. The advanced materials and technology used in manufacturing these stents, such as polyester fiber, ePTFE, and cutting-edge balloon-expandable designs, contribute to their premium pricing. For instance, the GORE VIABAHN VBX Stent Graft, known for its long balloon-expandable configuration, offers significant benefits in treating complex vascular conditions but comes at a higher cost compared to traditional solutions. This price barrier can result in unequal access to treatment, with healthcare systems in lower-income countries struggling to provide such high-cost interventions. Additionally, even in developed markets, the overall treatment costs factoring in surgery, follow-up care, and potential complications—may strain hospital budgets and healthcare providers. As a result, the high cost remains a critical challenge for widespread adoption and poses a potential roadblock to the growth of the aortic stent grafts market.

• Complications and Risks Associated with Aortic Stent Grafts

Complications and risks associated with aortic stent grafts represent a significant challenge in the market, despite the technology’s intended goal of reducing surgery-related risks. Issues such as graft migration, endoleaks, and infection can still arise after implantation, complicating patient recovery and requiring additional procedures. For instance, endoleaks, which occur when blood flows outside the stent graft, can lead to aneurysm rupture if not addressed, necessitating further intervention and extended hospital stays. Similarly, graft migration, where the stent shifts from its intended position, can compromise the effectiveness of the treatment and may require replacement or repositioning. These complications increase the overall cost of treatment and can deter both patients and healthcare providers from opting for stent grafts, as the need for additional surgeries and long-term monitoring adds significant financial and health risks. As a result, the occurrence of such complications remains a key challenge for the aortic stent graft market, hindering its potential for wider adoption and growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Aortic Stent Grafts Market Scope

The market is segmented on the basis of product and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Abdominal Aortic Stent Graft
• Thoracic Aortic Stent Graft

End User

• Hospitals
• Ambulatory Surgical Centers

Aortic Stent Grafts Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a leading position in the aortic stent grafts market, driven by continuous technological advancements and innovative product developments in the region. Companies in North America actively engage in research, ensuring the launch of cutting-edge solutions for vascular disease treatment. Furthermore, strong collaborations and strategic agreements among industry players and healthcare institutions bolster market growth. This dynamic ecosystem positions North America as a hub for innovation and leadership in the aortic stent graft sector.

Asia-Pacific region is projected to experience the fastest growth in the aortic stent graft market during the forecast period of 2025-2032. This rapid expansion is primarily driven by an increasing geriatric population, which is more prone to cardiovascular conditions. Additionally, the rising prevalence of cardiovascular diseases and hypertension in the region further fuels demand for advanced treatment solutions. These factors, coupled with improving healthcare infrastructure and greater awareness, are contributing to the region's growth potential.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Aortic Stent Grafts Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Aortic Stent Grafts Market Leaders Operating in the Market Are:

• Cardiatis (Belgium)
• Cook (U.S.)
• Endologix LLC (U.S.)
• Jotec (Germany)
• Part of ASSA ABLOY (Sweden)
• Terumo Aortic (Japan)
• MicroPort Scientific Corporation (China)
• Medtronic (Ireland)
• W. L. Gore & Associates, Inc. (U.S.)
• Corcym (Italy)
• Edwards Lifesciences Corporation (U.S.)
• Bentley Healthcare Pvt. Ltd. (India)
• Braile Biomédica (Brazil)
• Cardinal Health (U.S.)
• InSitu Technologies Inc. (U.S.)
• LeMaitre Vascular, Inc. (U.S.)

Latest Developments in Aortic Stent Grafts Market

• In August 2024, Terumo India, the Indian subsidiary of Japan-based Terumo Corporation, a global leader in medical technology, announced the launch of the TREO Stent-Graft System, an innovative solution for Endovascular Aneurysm Repair (EVAR)
• In July 2024, Endospan announced a new agreement with Artivion for additional loans totaling up to USD 25 million. Artivion, which operates in over 100 countries, offers a range of products including aortic stent grafts, surgical sealants, mechanical heart valves, and implantable cardiac and vascular human tissue. The funding aims to support Endospan’s efforts to secure FDA approval for its Nexus Stent Graft System
• In January 2024, W. L. Gore & Associates, Inc. (Gore) announced FDA approval for a lower-profile version of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft). This approval enhances a device already recognized as a vital tool for managing complex vascular diseases. The updated VBX Stent Graft features the longest balloon-expandable stent on the market (79 mm), the widest range of stent diameter adjustability, and the highest number of 6 Fr compatible configurations among balloon-expandable stent grafts
• In June 2023, Endospan shared the initial European experience with its NEXUS DUO Aortic Arch Stent Graft System at the Leipzig Interventional Course (LINC). The multicenter study showcased the first ten patients treated with this custom-made system
• In May 2021, Endologix LLC announced the first implant of its ALTO Abdominal Stent Graft in Canada following Health Canada approval. The device was also recently approved for commercial sale in Argentina

SKU-63035